Compare CODA & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CODA | WHWK |
|---|---|---|
| Founded | 1994 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.4M | 95.2M |
| IPO Year | 2007 | N/A |
| Metric | CODA | WHWK |
|---|---|---|
| Price | $13.71 | $3.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 331.6K | 143.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.62 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $20,316,161.00 | N/A |
| Revenue This Year | $16.42 | N/A |
| Revenue Next Year | $14.43 | N/A |
| P/E Ratio | $160.69 | ★ N/A |
| Revenue Growth | ★ 4.98 | N/A |
| 52 Week Low | $5.76 | $1.39 |
| 52 Week High | $18.00 | $4.40 |
| Indicator | CODA | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 50.29 | 67.87 |
| Support Level | $13.01 | $1.84 |
| Resistance Level | $14.89 | $4.40 |
| Average True Range (ATR) | 1.23 | 0.28 |
| MACD | -0.22 | 0.03 |
| Stochastic Oscillator | 19.36 | 66.08 |
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.